A validated HPLC technique for determining Irinotecan Hydrochloride (IRN) in pharmaceutical formulations was developed. For this chromatographic investigation, isocratic elution at a flow rate of 1.0 ml/min was utilized on Zorbax C18 150mm 4.6 mm, 5μ, or similar. The mobile phase is made up of 45 volumes of methanol and 55 volumes of buffer solution. The UV detection wavelength was 220 nm, and a sample of 10.0 μl was injected. The run time for Sample, Unmarked, Placebo, System Suitability and Sensitivity solutions is approximately 12 minutes, and 60 minutes for diluted Regular. The approximate retention time for IRN was determined to be 3.8 minutes. The percentage R.S.D. IRN was determined. Irinotecan's mean percentage recovery is found to be within the specified limit. The approach was validated in accordance with ICH recommendations. As a result, the suggested HPLC approach may be successfully used for routine formulation quality control examination. The devised approach is simple and superior to the methods published in the literature.